All In Biotech

Drug Trial Radar · NCT00671255

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Elderly Subjects With Chronic Insomnia

Last checked: Nov 20, 2026Latest source record: Feb 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 829 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

829

Actual

Start

Dec 2002

Primary completion

Jan 2004

Study completion Jan 2004

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This purpose of this study is to evaluate the safety and effectiveness of Ramelteon, once daily (QD), in elderly participants with chronic insomnia.

Conditions

  • Chronic Insomnia

Interventions

  • RamelteonDrug

    Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.

  • RamelteonDrug

    Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.

  • PlaceboDrug

    Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Subjective Sleep Latency per subject diary, from Nights 1 through 7 of double-blind TreatmentTime frame: Weeks 1, 2, 3, 4 and 5 or Final Visit.

Locations

115 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Columbiana, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Muscle Shoals, Alabama

  • Site not named

    Tallahassee, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tempe, Arizona

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Encinitas, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    La Mesa, California

  • Site not named

    Los Angeles, California

  • Site not named

    Murrieta, California

  • Site not named

    Northridge, California

  • Site not named

    Oakland, California

  • Site not named

    Redlands, California

  • Site not named

    Riverside, California

  • Site not named

    Rosemead, California

  • Site not named

    San Diego, California

  • Site not named

    Spring Valley, California

  • Site not named

    Vista, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Clearwater, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Longwood, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Pinellas Park, Florida

  • Site not named

    Safety Harbor, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Vero Beach, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Winter Park, Florida

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.